Esperion Completes ArchiMED Buyout, Delists from Nasdaq with $100M CVR
ESPR has more than doubled off its 52-week low of $1.1 on elevated volume (3.8× avg).
Summary
Esperion's acquisition by ArchiMED closed on July 13, triggering the delisting from Nasdaq. Shareholders receive $3.16 per share in cash plus contingent value rights (CVRs) worth up to $100 million based on future milestones. The stock will cease trading following the Form 25 filing. This follows the shareholder approval on July 8 and the expiration of antitrust waiting periods. The CVRs, administered by Computershare, tie additional payouts to specific achievements, adding a speculative element for former shareholders.
At the time of this announcement, ESPR was trading at $3.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $819.5M. The 52-week trading range was $1.10 to $4.18. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.